Jubilant Pharmova Reports 49% Surge in Profit After Tax to Rs 103 Crore
Jubilant Pharmova, a leading pharmaceutical company, has reported a significant 49% increase in profit after tax (PAT) to Rs 103 crore for the first quarter ended June 30, 2025. This marks a robust performance, driven by consistent revenue growth across all business units.
Jubilant PharmovaProfit After TaxPharmaceuticalsRevenue GrowthBusiness UnitsReal Estate PuneJul 29, 2025
The company said the reported PAT in Q1 of FY25 stood at Rs 482 crore due to one-time net exceptional income of Rs 396 crore. Revenue from operations rose to Rs 1,901 crore in the April-June quarter as compared with Rs 1,732 crore in the year-ago period, Jubilant Pharmova said in a regulatory filing.
It is heartening to note that we delivered solid revenue growth across all of our business units, and we expect this growth momentum to grow stronger as we move forward, Jubilant Pharmova Chairman Shyam S Bhartia said. Jubilant Pharmova shares were trading 1.88 per cent down at Rs 1,151.70 apiece on BSE.
Jubilant Pharmova, a leading player in the pharmaceutical and life sciences industries, has been consistently focusing on innovation and strategic partnerships to drive its growth. The company's strong performance in the first quarter of FY25 is a testament to its robust business model and effective operational strategies.
The one-time net exceptional income of Rs 396 crore in the reported PAT for Q1 FY25 is a significant factor contributing to the company's strong financial results. This income primarily stems from the successful execution of several strategic initiatives and the realization of assets that have been under development.
Looking ahead, Jubilant Pharmova is poised to continue its growth trajectory, driven by its focus on research and development, expansion into new markets, and the introduction of innovative products. The company's commitment to quality and customer satisfaction remains unwavering, and it is well-positioned to capitalize on the growing demand for pharmaceutical and life sciences solutions in the global market.
Disclaimer: This story is from the syndicated feed. Nothing has changed except the headline.
Frequently Asked Questions
What was Jubilant Pharmova's profit after tax (PAT) for Q1 FY25?
Jubilant Pharmova reported a profit after tax (PAT) of Rs 103 crore for Q1 FY25, marking a 49% increase from the previous year.
What was the normalized PAT for the June quarter of the last fiscal?
The normalized profit after tax (PAT) for the June quarter of the last fiscal was Rs 69 crore.
What was the reported PAT in Q1 of FY25 and why?
The reported PAT in Q1 of FY25 stood at Rs 482 crore due to a one-time net exceptional income of Rs 396 crore.
How much did the revenue from operations increase in the April-June quarter?
Revenue from operations rose to Rs 1,901 crore in the April-June quarter, up from Rs 1,732 crore in the year-ago period.
What is Jubilant Pharmova's focus for future growth?
Jubilant Pharmova is focusing on innovation, strategic partnerships, expansion into new markets, and the introduction of innovative products to drive future growth.
Related News Articles
Elevating Civil Aviation: Mohol's Pioneering Role in Pune
Discover how Mohol is driving growth in Pune's civil aviation sector, with insights from Hemant Rasne, former Mayor and BJP leader.
Budget 2024: A Boost to Sustainable Growth in Real Estate
The Union Budget 2024 focuses on MSMEs, employment, skilling, youth, and middle-class, with indirect benefits to the real estate sector through job creation, infrastructure, and urban redevelopment.
Dubai Real Estate Market Sets AED 141.9 Billion Quarterly Sales Record in Q3 2024
Dubai’s real estate market achieved a significant milestone in Q3 2024, with total sales reaching AED 141.9 billion, marking a new all-time high for a single quarter. This achievement surpassed the previous record of AED 124.07 billion set in Q2 2024, ref
Elan Group Gets a Boost with Rs 1200 Crore from Kotak Real Estate Fund
The investment will serve as growth capital, helping Elan Group cement its position in the thriving real estate market of Gurugram. This strategic move is expected to accelerate the company's expansion and development projects in the region.
Delhi-NCR: The Metro City Witnessing a Massive Surge in Housing Prices
The report suggests that the price appreciation in Delhi-NCR is attributed to rising demand for high-end properties. Read more to know the details.
Radisson Resort Khopoli Launches as a Luxurious Getaway Near Mumbai and Pune
Radisson Hotel Group has expanded its footprint in Maharashtra with the opening of Radisson Resort Khopoli, offering a premium retreat for travelers near Mumbai and Pune.